4.7 Article

Quantitative MRI in hypomyelinating disorders: Correlation with motor handicap

Journal

NEUROLOGY
Volume 87, Issue 8, Pages 752-758

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000003000

Keywords

-

Funding

  1. Dutch Organization for Scientific Research (ZonMw, TOP Grant) [9120.6002]
  2. Optimix Foundation for Scientific Research

Ask authors/readers for more resources

Objective:To assess the correlation of tissue parameters estimated by quantitative magnetic resonance (MR) techniques and motor handicap in patients with hypomyelination.Methods:Twenty-eight patients with different causes of hypomyelination (12 males, 16 females; mean age 10 years) and 61 controls (33 males, 28 females; mean age 8 years) were prospectively investigated. We quantified T2 relaxation time, magnetization transfer ratio, fractional anisotropy, mean, axial, and radial diffusivities, and brain metabolites. We performed measurements in the splenium, parietal deep white matter, and corticospinal tracts in the centrum semiovale. We further analyzed diffusion measures using tract-based spatial statistics. We estimated severity of motor handicap by the gross motor function classification system. We evaluated correlation of handicap with MR measures by linear regression analyses.Results:Fractional anisotropy, magnetization transfer ratio, choline, and N-acetylaspartate/creatine ratio were lower and diffusivities, T2 values, and inositol were higher in patients than in controls. Tract-based spatial statistics showed that these changes were widespread for fractional anisotropy (96% of the white matter skeleton), radial (93%) and mean (84%) diffusivity, and less so for axial diffusivity (20%). Correlation with handicap yielded radial diffusivity and N-acetylaspartate/creatine ratio as strongest independent explanatory variables.Conclusions:Gross motor function classification system grades are in part explained by MR measures. They indicate that mainly lack of myelin and, to a lesser degree, loss of axonal integrity codetermine the degree of motor handicap in patients with hypomyelinating disorders. These MR measures can be used to evaluate strategies that are aimed at promotion of myelination.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging

Rosa Cortese, Ferran Prados Carrasco, Carmen Tur, Alessia Bianchi, Wallace Brownlee, Floriana De Angelis, Isabel de la Paz, Francesco Grussu, Lukas Haider, Anu Jacob, Baris Kanber, Lise Magnollay, Richard S. Nicholas, Anand Trip, Marios Yiannakas, Ahmed T. Toosy, Yael Hacohen, Frederik Barkhof, Olga Ciccarelli

Summary: This study investigated whether imaging characteristics could differentiate between relapsing-remitting multiple sclerosis (RRMS), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The results showed that the proportion of lesions with the central vein sign (CVS) was the most accurate measure to differentiate RRMS from AQP4-NMOSD, while white matter lesions were the most accurate measure to discriminate RRMS from MOGAD.

NEUROLOGY (2023)

Letter Clinical Neurology

MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill? Reply

P. M. Cogswell, C. R. Jack Jr, J. A. Barakos, F. Barkhof, T. S. Benzinger, C. A. Raji, T. Y. Poussaint, V. K. Ramanan, C. T. Whitlow

AMERICAN JOURNAL OF NEURORADIOLOGY (2023)

Review Clinical Neurology

Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence

Zoe Mendelsohn, Hugh G. Pemberton, James Gray, Olivia Goodkin, Ferran Prados Carrasco, Michael Scheel, Jawed Nawabi, Frederik Barkhof

Summary: This article provides a systematic review of commercial QReports for multiple sclerosis (MS), highlighting limited evidence regarding clinical validation and in-use evaluation, particularly the lack of clinician end-user testing. The review aims to provide clinicians and institutions with the available evidence when considering adopting a quantitative reporting tool for MS.

NEURORADIOLOGY (2023)

Review Clinical Neurology

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

Lyduine E. Collij, Gill Farrar, David Vallez Garcia, Ilona Bader, Mahnaz Shekari, Luigi Lorenzini, Hugh Pemberton, Daniele Altomare, Sandra Pla, Mery Loor, Pawel Markiewicz, Maqsood Yaqub, Christopher Buckley, Giovanni B. Frisoni, Agneta Nordberg, Pierre Payoux, Andrew Stephens, Rossella Gismondi, Pieter Jelle Visser, Lisa Ford, Mark Schmidt, Cindy Birck, Jean Georges, Anja Mett, Zuzana Walker, Merce Boada, Alexander Drzezga, Rik Vandenberghe, Bernard Hanseeuw, Frank Jessen, Michael Scholl, Craig Ritchie, Isadora Lopes Alves, Juan Domingo Gispert, Frederik Barkhof, AMYPAD Consortium

Summary: Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium aims to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in AD diagnosis and support clinical trial design. AMYPAD has contributed significantly to understanding of amyloid deposition in the brain and improving measurement methodology. Future steps include integrating and curating available clinical data for wider scientific access.

FRONTIERS IN NEUROLOGY (2023)

Article Clinical Neurology

Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis

Floor C. Loonstra, Lodewijk R. J. de Ruiter, Marleen J. A. Koel-Simmelink, Menno M. Schoonheim, Eva M. M. Strijbis, Bastiaan Moraal, Frederik Barkhof, Bernard M. J. Uitdehaag, Charlotte Teunissen, Joep Killestein

Summary: This study explores the association between novel blood biomarkers (sNfL, sGFAP, and sCNTN1) and disability outcome measures and MRI volumes in people with multiple sclerosis (MS). The results indicate that sNfL and sGFAP are associated with disease progression, while sCNTN1 is not related to clinical or MRI measures.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Clinical Neurology

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets A MAGNIFY-MS Substudy

Heinz Wiendl, Klaus Schmierer, Suzanne Hodgkinson, Tobias Derfuss, Andrew Chan, Finn Sellebjerg, Anat Achiron, Xavier Montalban, Alexandre Prat, Nicola De Stefano, Frederik Barkhof, Letizia Leocani, Patrick Vermersch, Anita Chudecka, Claire Mwape, Kristina H. Holmberg, Ursula Boschert, Sanjeev Roy, MAGNIFY-MS Study Grp

Summary: Cladribine tablets cause a reduction in lymphocytes, with a predominant effect on B-cell and T-cell counts. The MAGNIFY-MS substudy reports the dynamic changes on multiple peripheral blood mononuclear cell (PBMC) subtypes and immunoglobulin (Ig) levels over 12 months after the first course of cladribine tablets in patients with highly active relapsing multiple sclerosis (MS).

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Neurosciences

MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies

Anna Inguanzo, Konstantinos Poulakis, Rosaleena Mohanty, Christopher G. Schwarz, Scott A. Przybelski, Patricia Diaz-Galvan, Val J. Lowe, Bradley F. Boeve, Afina W. Lemstra, Marleen van de Beek, Wiesje van der Flier, Frederik Barkhof, Frederic Blanc, Paulo Loureiro de Sousa, Nathalie Philippi, Benjamin Cretin, Catherine Demuynck, Zuzana Nedelska, Jakub Hort, Barbara Segura, Carme Junque, Ketil Oppedal, Dag Aarsland, Eric Westman, Kejal Kantarci, Daniel Ferreira

Summary: Using MRI data, we identified three subtypes of Dementia with Lewy bodies (DLB): older subtype with reduced cortical GM volumes and worse cognition, subtype with low GM volumes in fronto-occipital regions, and a younger subtype with the highest cortical GM volumes, lower GM volumes in basal ganglia, and cognitive fluctuations. These subtypes have implications for clinical practice, research, and treatment decisions.

NPJ PARKINSONS DISEASE (2023)

Review Clinical Neurology

Longitudinal amyloid and tau PET imaging in Alzheimer's disease: A systematic review of methodologies and factors affecting quantification

Ariane G. Bollack, Hugh G. E. Pemberton, Lyduine E. Collij, Pawel M. Markiewicz, David M. Cash, Gill Farrar, Frederik Barkhof

Summary: This review summarizes the current design and methodologies of longitudinal PET studies, utilizing positron emission tomography to quantify amyloid and tau pathology. The intrinsic variability of AD protein load over time and technical factors contributing to PET measurement uncertainty are detailed. Suggestions for mitigating these factors, including leveraging shared information between serial scans, are provided.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease

Liu Shi, Jin Xu, Rebecca Green, Asger Wretlind, Jan Homann, Noel J. Buckley, Betty M. Tijms, Stephanie J. B. Vos, Christina M. Lill, Mara ten Kate, Sebastiaan Engelborghs, Kristel Sleegers, Giovanni B. Frisoni, Anders Wallin, Alberto Lleo, Julius Popp, Pablo Martinez-Lage, Johannes Streffer, Frederik Barkhof, Henrik Zetterberg, Pieter Jelle Visser, Simon Lovestone, Lars Bertram, Alejo J. Nevado-Holgado, Petroula Proitsi, Cristina Legido-Quigley

Summary: This study employed an integrative system and causal inference approach to explore molecular signatures in blood and CSF, the AT(N) framework, MCI conversion to AD, and genetic risk for AD. Using the EMIF-AD cohort, the researchers measured proteins and metabolites in blood and CSF, as well as genotyped whole-blood samples. They found associations between AT(N) framework and protein/lipid hubs, and identified Proprotein Convertase Subtilisin/Kexin Type 7 as a potential causative factor for AD.

ALZHEIMERS & DEMENTIA (2023)

Article Clinical Neurology

Genetically identical twin-pair difference models support the amyloid cascade hypothesis

Emma M. Coomans, Jori Tomassen, Rik Ossenkoppele, Betty M. Tijms, Luigi Lorenzini, Mara ten Kate, Lyduine E. Collij, Fiona Heeman, Roos M. Rikken, Sophie M. van der Landen, Marijke E. den Hollander, Sandeep S. Golla, Maqsood Yaqub, Albert D. Windhorst, Frederik Barkhof, Philip Scheltens, Eco J. C. de Geus, Pieter Jelle Visser, Bart N. M. van Berckel, Anouk den Braber

Summary: The amyloid cascade hypothesis has played a significant role in Alzheimer's disease research and clinical trial designs. This study investigated the relationship between amyloid-beta and tau at the individual and twin-pair levels, aiming to rule out genetic and shared environmental effects as confounders. The findings suggest that the associations between amyloid-beta, tau, neurodegeneration, and cognition are unbiased by genetic factors, and the effects of amyloid-beta on neurodegeneration and cognitive decline are mediated by tau.

BRAIN (2023)

Article Clinical Neurology

Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis

Diana I. Bocancea, Anna L. Svenningsson, Anna C. van Loenhoud, Colin Groot, Frederik Barkhof, Olof Strandberg, Ruben Smith, Renaud La Joie, Howard J. Rosen, Michael J. Pontecorvo, Gil D. Rabinovici, Wiesje M. van der Flier, Oskar Hansson, Rik Ossenkoppele

Summary: The mechanisms of resilience against tau pathology in Alzheimer's disease spectrum are not well understood. This longitudinal study investigates the factors that contribute to cognitive and brain resilience against tau pathology and finds that education is the most important determinant of resilience. However, resilience may be depleted in advanced stages of the disease.

BRAIN (2023)

Article Neurosciences

Transferability of Alzheimer?s disease progression subtypes to an independent population cohort

Hanyi Chen, Alexandra Young, Neil P. Oxtoby, Frederik Barkhof, Daniel C. Alexander, Andre Altmann

Summary: This study examines the generalisability of data-driven Alzheimer's disease (AD) progression models using the SuStaIn algorithm. The results show consistent subtypes of atrophy in both datasets and high consistency in individuals' subtypes and stage assignments. The study also reveals associations between AD atrophy subtypes and risk factors.

NEUROIMAGE (2023)

Editorial Material Clinical Neurology

Brain Shrinkage in Anti-β-Amyloid Alzheimer Trials Neurodegeneration or Pseudoatrophy?

Frederik Barkhof, David S. Knopman

Summary: One puzzling observation in Alzheimer's disease therapeutic trials is that treatment with anti-amyloid-beta agents does not preserve brain volume. In a recent study, Alves et al. conducted a meta-analysis and found that these agents do not slow the rate of brain volume loss. In fact, depending on the drug class, they can even accelerate loss of whole-brain and hippocampal volume and increase ventricular volume.

NEUROLOGY (2023)

Article Neurosciences

Evaluation of novel data-driven metrics of amyloid β deposition for longitudinal PET studies

Ariane Bollack, Pawel J. Markiewicz, Alle Meije Wink, Lloyd Prosser, Johan Lilja, Pierrick Bourgeat, Jonathan M. Schott, William Coath, Lyduine E. Collij, Hugh G. Pemberton, Gill Farrar, Frederik Barkhof, David M. Cash

Summary: This study evaluated the performance of four novel data-driven metrics against conventional techniques for quantifying amyloid-beta (Aβ) pathology. The results showed that the Aβ load, Aβ index, and CLNMF metrics can provide comparable performance to established quantification methods. These new metrics may offer more precise alternatives and further studies in larger cohorts should be conducted.

NEUROIMAGE (2023)

Article Clinical Neurology

Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies

Emma M. Coomans, Lotte A. de Koning, Roos M. Rikken, Sander C. J. Verfaillie, Denise Visser, Anouk den Braber, Jori Tomassen, Marleen van de Beek, Lyduine E. Collij, Afina W. Lemstra, Albert D. Windhorst, Frederik Barkhof, Sandeep S. V. Golla, Pieter Jelle Visser, Philip Scheltens, Wiesje M. van der Flier, Rik Ossenkoppele, Bart N. M. van Berckel, Elsmarieke van de Giessen

Summary: This study evaluated the performance of the visual read method in participants along the AD continuum and dementia with Lewy bodies (DLB), showing excellent inter-reader agreement, strong correspondence with semiquantification, and associations with clinically relevant variables. The visual read status remained stable over a two-year follow-up period and was associated with a decline in Mini-Mental State Examination scores, indicating its reliability and prognostic potential. Future studies in unselected cohorts are needed for better generalizability to the clinical population.

NEUROLOGY (2023)

No Data Available